|
| |
Dr Kwekkeboom, MD, did his thesis on pituitary adenomas in 1989 and from 1990
to 1994 worked as a research associate at the Department of Nuclear Medicine in
Rotterdam, investigating the value of somatostatin receptor imaging in patients with
neuroendocrine and other receptor expressing tumors. He registered as nuclear
medicine physician in 1998 and from then on worked as a staff member at the
Department of Nuclear Medicine at the University Hospital Rotterdam. His major
research topic is peptide receptor imaging and he coordinates the studies on therapy
with the radiolabelled somatin analogue 177Lu-octreotate in patients with
neuroendocrine tumors. He has numerous publications in international journals and
textbooks, mainly in the field of endocrinology and peptide receptor scintigraphy
and therapy.
Dr Krenning completed his MD in 1972 and achieved a PhD by thesis at the
University of Rotterdam in 1983. He has at present positions as Head of Department of
Nuclear Medicine at the University Hospital, Rotterdam (since 1985), Professor of
Nuclear Medicine (since 1990), and was made a Fellow of the Royal College of
Physicians, London, UK, in 1999. Dr Krenning has participated in the educational
responsibilities at the University Hospital Rotterdam, lecturing in Internal
Medicine, Nuclear Medicine and Endocrinology throughout his career. Dr Krenning has
been involved in research since 1975. His main interests include thyroidology and
radioactive labelled peptides with their introduction into imaging and radionuclide
therapy. Dr Krenning has been the (co)author of more than 250 peer-reviewed articles
since 1975, more than 150 chapters and proceedings in the field of thyroidology and
peptide receptor scintigraphy and therapy.
|
|
